Isomorphic Labs, a London company that designs new medicines with AI, said on Nov. 17 that it has raised $5 billion. Greenoaks and Sequoia Capital led the round, joined by Andreessen Horowitz and several other new investors. Alphabet invested again, and every earlier investor took part, including Thrive Capital, Temasek and the UK Sovereign AI Fund. Isomorphic last raised money in May, when it took in $2.1 billion in a round led by Thrive Capital.
The company is run by Demis Hassabis, who co-founded Google DeepMind and is now its chair. He stepped back as DeepMind's chief executive in August, according to a news report. He received the 2024 Nobel Prize in Chemistry for AlphaFold, an AI system that predicts the structure of proteins. Isomorphic was founded in 2021 to change how drugs are discovered with AI.
Its drug design engine, which it calls IsoDDE, is a set of AI models. Isomorphic says they simulate how molecules behave and search a vast range of possible chemicals, so its scientists can design and refine molecules with the traits a medicine needs. Max Jaderberg, Isomorphic's president, says the models bring new scientific advances every week, but the announcement gives no data to back that up.
Isomorphic says its drug candidates, the molecules it hopes will become medicines, have shown positive results in preclinical tests, both in its own cancer and immune-disease programs and with partners. Those are the laboratory studies that check whether a drug may cause serious harm before it is tested in people. The company says these results set the stage for its first clinical trials, the studies done in people. Hassabis says the round will drive the company's first programs toward those trials.
Isomorphic says the money will also pay for more advanced AI models, a network of research partners and the systems it needs to take drug candidates into trials. The round comes in a year when drug discovery startups have raised $23.2 billion, more than in any year before, according to a news report. Isomorphic's announcement gives no valuation, no date for its first trial and no name for the first drugs.